Literature DB >> 10321734

Inactivation of the p53-homologue p73 by the mdm2-oncoprotein.

M Dobbelstein1, S Wienzek, C König, J Roth.   

Abstract

The p73beta protein shares structural and functional similarities with the tumor suppressor gene product p53. Both proteins activate transcription from p53-responsive promoters. p53's activity is antagonized by the mdm2 protein (also termed hdm2 in human cells). Complex formation between p53 and mdm2 results in p53's transcriptional inactivation and destabilization. Here we show that overexpression of mdm2 reduces p73beta's ability to activate transcription, too. The mdm2 protein forms a specific complex with p73beta in vitro with an efficiency comparable to p53-binding. Further, both p73beta and p53 relocalize a transport-defective mutant of mdm2 from the cytoplasm to the nucleus, arguing that complex formation occurs in vivo as well. Mutational analysis suggests that the interaction between p73beta and mdm2 follows structural principles analogous to the p53-mdm2-complex. Whereas p53 is destabilized in the presence of mdm2, the amount of intracellular p73beta was not detectably reduced by mdm2. The carboxyterminal RING finger domain of mdm2 was found to be required to reduce the intracellular abundance of p53, but it was dispensable for transcriptionally inactivating either p53 or p73beta. Our results suggest that the autoregulatory feedback loop between p53 and mdm2 also controls p73's activity, but that mdm2-mediated protein degradation is unique to p53.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321734     DOI: 10.1038/sj.onc.1202512

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Identification of a sequence element from p53 that signals for Mdm2-targeted degradation.

Authors:  J Gu; D Chen; J Rosenblum; R M Rubin; Z M Yuan
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe Ki; Satoru Todo; Hiroyuki Mizuguchi; Takao Hayakawa; Akira Nakagawara
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

4.  Transcriptional activation by the PHD finger is inhibited through an adjacent leucine zipper that binds 14-3-3 proteins.

Authors:  T Halbach; N Scheer; W Werr
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

5.  DeltaNp73beta is active in transactivation and growth suppression.

Authors:  Gang Liu; Susan Nozell; Hui Xiao; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

6.  Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Authors:  Tongsen Zheng; Jiabei Wang; Xuan Song; Xianzhi Meng; Shangha Pan; Hongchi Jiang; Lianxin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-20       Impact factor: 4.553

Review 7.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

8.  Pathway crosstalk analysis of microarray gene expression profile in human hepatocellular carcinoma.

Authors:  Xiaodong Zhou; Ruiguo Zheng; Huifang Zhang; Tianlin He
Journal:  Pathol Oncol Res       Date:  2014-12-06       Impact factor: 3.201

9.  The expression of p73, p21 and MDM2 proteins in gliomas.

Authors:  Makoto Kamiya; Yoichi Nakazato
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

10.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.